CB34 x CB48 targeting cancer therapy - Cartography Biosciences
Latest Information Update: 05 Nov 2024
Price :
$50 *
At a glance
- Originator Cartography Biosciences
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 31 Aug 2024 Early research in Solid tumours in USA (Parenteral) (Cartography Biosciences pipeline; August 2024)